期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿德福韦酯治疗HBeAg阳性慢性乙型肝炎29例疗效观察 被引量：1

下载PDF
导出
摘要 目的评价阿德福韦酯(ADV)10 mg/d治疗HBeAg阳性慢性乙型肝炎患者的疗效和安全性。方法采取随机、对照的研究设计,第一阶段29例患者随机分为治疗组20例(ADV治疗)和对照组9例(凯西来)治疗12周;第二阶段所有患者均接受ADV治疗36周,治疗48周时评价疗效。主要疗效评价指标为血清乙型肝炎病毒脱氧核糖核酸(HBV DNA)的变化情况;次要疗效评价指标为丙氨酸氨基转移酶(ALT)的复常率、肝组织病理改善率、HBeAg转阴率及HBeAg/HBeAb血清转换率。结果治疗12周时,治疗组和对照组HBV DNA分别为(4.2±1.2)lg拷贝/ml和(7.5±0.8)lg拷贝/ml,差异有统计学意义(P<0.01);48周时治疗组HBVDNA为(3.4±1.1)lg拷贝/ml,与基线水平[(8.5±0.8)lg拷贝/ml]比较,差异有统计学意义(P<0.01)。对HBV DNA的有效抑制率为100%,HBV DNA转阴率60.0%,ALT复常率100%,HBeAg转阴率45.0%,HBeAg/HBeAb血清转换率10.0%,肝组织病理改善率66.7%。治疗期间未发现严重不良反应。结论阿德福韦酯10 mg/d服用48周,可以安全、有效地治疗HBeAg阳性的慢性乙型肝炎患者。
作者 李丹 潘晨 郑玲 吕旭江
机构地区 福州市肺科医院 福州市传染病医院
出处 《福建医药杂志》 CAS 2007年第3期32-34,共3页 Fujian Medical Journal
关键词 阿德福韦酯 HBEAG阳性 慢性乙型肝炎
分类号 R512.62 [医药卫生—内科学]
  • 相关文献

参考文献7

  • 1党晓燕,成军,邓红,张黎颖.阿德福韦在乙型肝炎中的应用现状[J].世界华人消化杂志,2005,13(1):61-63. 被引量：7
  • 2中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量：14014
  • 3Balzarini J,Hao Z,Herdewijn P,et al.Intracelluar metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl) adenine,a potent anti-human immuninodefieiency virus compound.Proc Natl Acad Sci USA.1991,88(4):1499-1503.
  • 4Seigneres B,Aguesse-Gernom S,Pichoud C,et al.Duck heparids B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.J Hepatol,2001,34(3):114-118.
  • 5曾民德,茅益民,姚光弼,周霞秋,王豪,徐道振,姚集鲁,侯金林,王宇明,任红,陈亚岗,牛俊奇,王耀宗.阿德福韦酯治疗HBeAg阳性的中国慢性乙型病毒性肝炎患者52周的多中心临床研究[J].中华传染病杂志,2005,23(6):387-394. 被引量：164
  • 6Patrick M,Ting-Tsung C,Seng GL,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med,2003,348(9):808-816.
  • 7Keamey B,Knight W,Currie G,et al.Adefovir dipivoxil salety and pharmacokinetics in subjects with hepatitis B virus infection and healthy subjects.J Hepatol,2002,36(Suppl 1):100-103.

二级参考文献37

  • 1Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C,Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297.
  • 2Cullen JM, Li DH, Brown C, Eisenberg EJ, Cundy KC, Wolfe J,Toole J, Gibbs C. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 2001;45:2740-2745.
  • 3Delaney WE 4th, Edwards R, Colledge D, Shaw T, Torresi J,Miller TG, Isom HC, Bock CT, Manns MP, Trautwein C,Locarnini S. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001;45:1705-1713.
  • 4Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ, Omata M. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;103:1635-1640.
  • 5Del Gobbo V, Foli A, Balzarini J, De Clercq E, Balestra E,Villani N, Marini S, Perno CF, Calio R. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res 1991;16:65-75.
  • 6Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT,Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil 438 study group. Adefovir dipivoxil for the treatment of hepatitis be antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
  • 7Delmas J, Schorr O, Jamard C, Gibbs C, Trepo C, Hantz O,Zoulim F. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002;46:425-433.
  • 8Shaw T, Locarnini SA. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver 1995;15:169-184.
  • 9Robbins BL, Greenhaw J, Connelly MC, Fridland A. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl) adenine in human lymphoid cells. Antimicrob Agents Chemother 1995;39:2304-2308.
  • 10Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A.Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine(PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Afents Chemother 1998;42:612-617.

共引文献14132

同被引文献2

引证文献1

福建医药杂志
2007年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部